Japanese MedTech company Terumo Medical Corporation, a subsidiary of Terumo Corporation, has announced the US launch of its SurTract Safety Syringe, powered by SafeR passive safety technology. Developed by Roncadelle Operations S.r.l, the SurTract Syringe will be distributed across hospitals, clinics, and emergency-care settings beginning in the first quarter of 2026.
SafeR technology provides the SurTract Syringe with a fully passive, automatic retraction mechanism that withdraws the needle into the plunger immediately after use, which the company says helps to reduce the risk of needle-stick injuries for physicians, and providing patients with a smooth and comfortable injection due to less plunger pressure.
“The SurTract Syringe combines Terumo’s trusted clinical know-how with Roncadelle’s validated SafeR technology to deliver a simple, effective solution for safer injections,” said Bob Klock, Vice President, Terumo Medical Corporation. “It gives healthcare providers more – and better – treatment options for their patients, which is our ultimate goal.”
“Terumo has significantly advanced injection safety with the integration of our SafeR technology,” said Dr. Fred Metzmann, Chief Business Development Officer at Roncadelle Operations. “Together, we are delivering a next-generation syringe system that is intuitive, reliable, and engineered to protect healthcare professionals.”
